![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXCL5 |
Gene summary for CXCL5 |
![]() |
Gene information | Species | Human | Gene symbol | CXCL5 | Gene ID | 6374 |
Gene name | C-X-C motif chemokine ligand 5 | |
Gene Alias | ENA-78 | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | P42830 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6374 | CXCL5 | ATC09 | Human | Thyroid | ATC | 1.01e-35 | 1.71e+00 | 0.2871 |
6374 | CXCL5 | ATC1 | Human | Thyroid | ATC | 2.88e-35 | 1.82e+00 | 0.2878 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Breast | Healthy |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Endometrium | EEC |
CXCL5 | CXCR2 | CXCL5_CXCR2 | CXCL | Endometrium | EEC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Esophagus | ESCC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | HNSCC | OSCC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | HNSCC | Precancer |
CXCL5 | CXCR2 | CXCL5_CXCR2 | CXCL | HNSCC | Precancer |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXCL5 | SNV | Missense_Mutation | c.122C>T | p.Ala41Val | p.A41V | P42830 | protein_coding | deleterious(0.02) | possibly_damaging(0.565) | TCGA-AA-3814-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | rs756143598 | c.224N>A | p.Cys75Tyr | p.C75Y | P42830 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CXCL5 | SNV | Missense_Mutation | c.314N>C | p.Lys105Thr | p.K105T | P42830 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | c.17G>T | p.Ser6Ile | p.S6I | P42830 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | c.58N>A | p.Ala20Thr | p.A20T | P42830 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
CXCL5 | SNV | Missense_Mutation | c.265G>A | p.Glu89Lys | p.E89K | P42830 | protein_coding | tolerated(0.32) | benign(0.122) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | novel | c.159N>T | p.Gln53His | p.Q53H | P42830 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CXCL5 | SNV | Missense_Mutation | novel | c.159N>T | p.Gln53His | p.Q53H | P42830 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXCL5 | SNV | Missense_Mutation | novel | c.231N>T | p.Lys77Asn | p.K77N | P42830 | protein_coding | tolerated(0.24) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CXCL5 | SNV | Missense_Mutation | novel | c.179N>A | p.Pro60His | p.P60H | P42830 | protein_coding | deleterious(0.03) | probably_damaging(0.977) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6374 | CXCL5 | DRUGGABLE GENOME | hmg coa reductase inhibitors | 18769620 |
Page: 1 |